Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IO Biotech ( (IOBT) ) just unveiled an announcement.
On January 21, 2026, IO Biotech announced that it had begun exploring a range of strategic alternatives aimed at maximizing shareholder value, including options such as a merger, business combination, sale of assets, other strategic transactions, or potentially liquidation and dissolution. As part of this review, the company is also considering additional workforce reductions and other significant cost-cutting measures, while noting that no timetable has been set, no transaction agreements have been reached, and there is no assurance that any deal will ultimately be pursued or completed on favorable terms, underscoring a period of heightened uncertainty for investors, employees, and partners.
The most recent analyst rating on (IOBT) stock is a Hold with a $0.48 price target. To see the full list of analyst forecasts on IO Biotech stock, see the IOBT Stock Forecast page.
Spark’s Take on IOBT Stock
According to Spark, TipRanks’ AI Analyst, IOBT is a Neutral.
The score is primarily held down by weak financial performance (pre-revenue, large losses, and significant cash burn with a thinner equity buffer). Technicals also remain bearish with the stock below key moving averages and negative MACD. Corporate events are mixed—delisting risk is a meaningful overhang, partly offset by encouraging (but not statistically decisive) Phase 3 updates—while valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on IOBT stock, click here.
More about IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company focused on developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win platform, which is designed to activate T cells against both tumor cells and immune-suppressive cells in the tumor microenvironment. The company is headquartered in Copenhagen, Denmark, with U.S. headquarters in New York, and targets oncology indications through its proprietary cancer vaccine technology.
Average Trading Volume: 1,026,484
Technical Sentiment Signal: Sell
Current Market Cap: $36.13M
See more insights into IOBT stock on TipRanks’ Stock Analysis page.